One year after flop, AstraZeneca's phase 3 lupus trial hits endpoint

A phase 3 trial of AstraZeneca’s anifrolumab in systemic lupus erythematosus has met its primary endpoint. The success comes one year after the anti-IFNAR1 antibody failed to move the needle in another late-phase lupus trial.